Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
Open Access
- 31 May 2004
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 34 (3), 229-234
- https://doi.org/10.1038/sj.bmt.1704562
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsBlood, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Impact of complete remission with intensive therapy in patients with responsive multiple myelomaBone Marrow Transplantation, 2001
- Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patientsBritish Journal of Haematology, 2000
- Autologous stem cell transplantation for relapsed and primary refractory myelomaBone Marrow Transplantation, 1999
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.Journal of Clinical Oncology, 1996
- High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1993
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990